Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:11/5/2008

pacity for future potential orders of pegloticase.

Selling, general and administrative expenses for the first nine months of 2008 were $27.3 million, an increase of $6.0 million or 28%. The increase is primarily due to higher legal costs resulting from patent infringement litigation and loss contingencies for the settlement of two legal proceedings, higher share-based compensation expense substantially due to an increase in the quantity of certain performance-based and service-based restricted stock awards and an increase in pre-launch pegloticase marketing and marketing research expenses as we prepare for the potential commercial launch of the product. Partially offsetting the above increases was a decrease in accounting and tax related professional fees.

Investment income for the first nine months of 2008 was $1.7 million, a decrease of $5.1 million or 75%. This decrease was primarily attributable to a decrease in dividend and interest income on lower cash, cash equivalent and investment balances and lower yields earned on these investments.

CONFERENCE CALL

Savient will host a live web cast to review third quarter 2008 results on November 6, 2008 at 10:00 a.m. EST. Both the live and archived web cast can be accessed from the Investor Relations page of Savient's website at http://www.savient.com. A digital recording of the web cast will be available within one hour following the conclusion of the call and will be available for 14 days. To access the recording, use the Dial-In Number and the Conference ID listed below.

Dial: (800) 642-1687 (domestic) or (706) 645-9291 (international)

Conf ID: 67897749

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Savient Submits Biologics License Application (BLA) for pegloticase
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
4. Onyx Pharmaceuticals to Present at the 2008 Credit Suisse Health Care Conference
5. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
6. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
7. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
8. Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
9. VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
10. OncoMed Pharmaceuticals Completes Series B Financing
11. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... (PRWEB) March 04, 2015 PRC ... in the San Francisco Bay Area, will exhibit and ... Israel Conference 2015 on March 25th and 26th ... to build relationships with Israeli life science companies seeking ... trials. The company’s services span all phases of human ...
(Date:3/4/2015)... , March 4, 2015  BioClinica®, Inc., ... technology provider, today announced that clinical trial ... convened at its annual European User Conference ... to discuss the use of its eClinical ... eClinical technologies include: the Microsoft Office-Smart OnPoint ...
(Date:3/4/2015)... , March 4, 2015 ... Paris in December 2011, ... of yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular ... expected late 2016.   SARAH, a large ... cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
Breaking Biology Technology:PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... is a saga that never ends. , ,Just as you complete ... timely achievement of key milestones you identified for your new investors ... and who the money will come from. Most angel investors aren't ... most VCs usually commit for two or more rounds but may ...
... exciting at the beginning. , ,Two companies enter into ... Web site, or have a service provider deliver a range ... work out perfectly well and the parties come to the ... has been performed or received. , ,However, sometimes the ...
... Criticare Systems Inc., which makes clinical patient monitors and sensors, ... ended March 31, on sales of $6 million. , ,Sales ... of 2004, but operating expenses were also down, and the ... Its reported cash balance held steady at about $3.7 million. ...
Cached Biology Technology:Financing of biotech companies so far in 2005: A Midwest odyssey 2Financing of biotech companies so far in 2005: A Midwest odyssey 3Financing of biotech companies so far in 2005: A Midwest odyssey 4Financing of biotech companies so far in 2005: A Midwest odyssey 5Arbitration can help when IT deals go sour 2Arbitration can help when IT deals go sour 3
(Date:2/19/2015)... 2015 Research and Markets ( ... "Military Electro-Optical / Infrared Systems Market by ... - Forecast to 2020" report to their ... market is expected to reach $16.35 billion by ... This report segments the military electro-optical/infrared systems ...
(Date:2/11/2015)... , February 11, 2015 ... research report "Access Control Market by Product (Cards and ... Residential, Military and Defense, Government, Industrial, Healthcare, Education) and ... published by MarketsandMarkets, the Access Control Market ... 2020, growing at a CAGR of 10.6% ...
(Date:2/5/2015)... 26, 2015   Epic Sciences , a precision diagnostics ... that Murali Prahalad , Ph.D., president and CEO, is ... (PMWC) 2015: Silicon Valley, which is taking place at ... on January 26-28, 2015. Dr. ... as Biomarkers." Last year, Epic Sciences was a finalist in ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... ago in Israel,s Negev Desert has yielded an ... related to some of the world,s most dangerous ... hosts. Researchers believe this attribute could ... for studying other alphaviruses, a genus of largely ...
... pipes and costing billions of dollars worldwide in odour control ... new research discussed at the 2012 International Water Association (IWA) ... chemicals, called Cloevis, on sewers in the Gold Coast region ... gas or hydrogen sulphide emitted from these pipes. Lead ...
... This press release is available in French . ... forests in Canada,s extreme north could one day return, according ... Geography, who is presenting his findings at the Canadian Paleontology ... conditions on Bylot Island will be able to support the ...
Cached Biology News:Mosquito virus could lead to new vaccines and drugs 2Mosquito virus could lead to new vaccines and drugs 3Solving the stink from sewers 2Nunavut's mysterious ancient life could return by 2100 2
... new Enzyme-Linked Immunosorbent Assay (ELISA) analyzer offering ... a dedicated EVO platform for reliableELISA Processing ... incubation units operated by the new sophisticated ... in three sizes - 100, 150, 200 ...
... hormones which belong to the transforming ... superfamily is a large group of ... aspects of development, reproductive function and ... TGF-s, bone morphogenetic proteins, growth differentiation ...
... Beads Sterile plating in just seconds ... and potentially hazardous ethanol flaming, More uniform ... ready-to-use sterile packaging: dispenser bottle for spreading 100 ... Fastest and easiest way to spread cells ...
... in a regulated environment, Pipette Tracker ... software that automates gravimetric pipette calibration ... that meets todays regulatory compliance requirements. ... solution that includes a full security ...
Biology Products: